# Ascendis Pharma A/S (ASND) stock: price and valuation

URL: https://funkfolio.com/stock/ASND

> Ascendis Pharma A/S (ASND) trades at $269.15, is worth $17.65B, is priced at 17.7× earnings and scores 55/100. Valuation, financials and signals.

---

## Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (ASND) is a healthcare company (biotechnology) based in Denmark. The share price is $269.15, down 0.95% on the day, which values the company at $17.65B. Price as of 17 Nov 2026, 19:14 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $269.15 −0.95% today
- **Market value:** $17.65B
- **P/E ratio:** 17.7× last 12 months
- **Forward P/E:** 22.2×
- **Funk Score:** 55/100
- **200-week average:** $160.87 67% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 19:14 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Ascendis Pharma A/S in more detail

ASND trades at 17.7× its last twelve months' earnings, 22.2× next year's expected earnings, 14.7× sales. It sits 67% above its 200-week average of $160.87.

Its Funk Score is 55 out of 100 (financial strength 3.8, profitability 2.6, growth 10.0, each out of 10).

In its favour: Operating margin is expanding. Worth checking: Share count keeps rising; Thin interest cover.

2 of the superinvestors tracked here hold ASND, including Peter Kolchinsky (23.8% of the portfolio), Polen Capital team (0.1% of the portfolio).

### Superinvestors holding ASND

2 of the investors tracked here report a position in their latest 13F filing.

- [Peter Kolchinsky RA Capital Management](https://funkfolio.com/gurus/peter-kolchinsky) 23.8% of portfolio · $2.7B · Q2 2026
- [Polen Capital team Polen Capital Management](https://funkfolio.com/gurus/polen-capital) 0.05% of portfolio · $5M · new · Q3 2026

### Health Care companies of similar size

- [Alnylam Pharmaceuticals ALNY](https://funkfolio.com/stock/ALNY)
- [Zimmer Biomet Holdings ZBH](https://funkfolio.com/stock/ZBH)
- [Medpace Holdings MEDP](https://funkfolio.com/stock/MEDP)
- [Revvity RVTY](https://funkfolio.com/stock/RVTY)
- [Exelixis EXEL](https://funkfolio.com/stock/EXEL)
- [Charles River Laboratories International CRL](https://funkfolio.com/stock/CRL)
- [Neurocrine Biosciences NBIX](https://funkfolio.com/stock/NBIX)
- [ICON ICLR](https://funkfolio.com/stock/ICLR)
- [Jazz Pharmaceuticals JAZZ](https://funkfolio.com/stock/JAZZ)
- [Solventum SOLV](https://funkfolio.com/stock/SOLV)
- [BridgeBio Pharma BBIO](https://funkfolio.com/stock/BBIO)
- [Summit Therapeutics SMMT](https://funkfolio.com/stock/SMMT)

Side by side: [ASND vs NBIX (Ascendis Pharma A/S vs Neurocrine Biosciences)](https://funkfolio.com/compare/asnd-vs-nbix) [ASND vs CRL (Ascendis Pharma A/S vs Charles River Laboratories International)](https://funkfolio.com/compare/asnd-vs-crl) [ASND vs EXEL (Ascendis Pharma A/S vs Exelixis)](https://funkfolio.com/compare/asnd-vs-exel) [ASND vs ICLR (Ascendis Pharma A/S vs ICON)](https://funkfolio.com/compare/asnd-vs-iclr) [ASND vs RVTY (Ascendis Pharma A/S vs Revvity)](https://funkfolio.com/compare/asnd-vs-rvty)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in Denmark](https://funkfolio.com/companies/country/denmark) [All stocks A–Z](https://funkfolio.com/stocks)

### Ascendis Pharma A/S (ASND): questions and answers

**What is ASND's P/E ratio?**

Ascendis Pharma A/S trades at 17.7× its last twelve months' earnings and 22.2× next year's expected earnings.

**What is Ascendis Pharma A/S's market cap?**

Ascendis Pharma A/S is valued at $17.65B at a share price of $269.15.

**Is ASND above its 200-week moving average?**

Yes. ASND is 67.3% above its 200-week average of $160.87. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Ascendis Pharma A/S growing?**

Over the last three fiscal years Ascendis Pharma A/S's revenue grew 141.4% a year.

**Does ASND pay a dividend?**

Ascendis Pharma A/S does not currently pay a regular dividend.

**Which famous investors own ASND?**

In their latest quarterly filings, Peter Kolchinsky (23.8% of the portfolio), Polen Capital team (0.1% of the portfolio) hold ASND. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Ascendis Pharma A/S (ASND) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ASND

Underlying data: Yahoo Finance; company filings with the SEC.
